John Petersen

Update Your Profile
Profile URL: www.utmb.edu/pathology/profiles/?user=jrpeters
John Petersen
Contact Information
Email:

Directory lookup

Academic Appointments
Appointment Organization
Professor Pathology
Research Interests

Clinical Methodologies

My research focuses on development of new clinical methodologies and the analytical validation of these methods. Development and timely testing of new methods introduced into the clinical laboratory are vital to give better and more cost effective patient care. During my career, I have held a number of positions of increasing responsibility in the diagnostic industry, which has focused my interest on development of products for the clinical laboratory and have subsequently led to the commercialization of a number of unique assays.

Although there is antidotal evidence that Point of Care Testing (POCT) helps in enhancing patient care, peer reviewed studies showing the impact POCT has on patient care is minimal. We are interested in identifying opportunities (evidenced based) in our POCT program that can show how POCT can be used to enhance the care of patients. An area that has been identified is in the use of transcutaneous bilirubin and its impact on neonatal care by early identification of hyperbilirubinemia which was found to reduce the readmission rate of babies for hyperbilirubinemia.

There is also a substantial body of literature that supports the concept that colorectal cancers arise slowly, as a result of incremental genetic alterations. This forms the basis of current clinical recommendations in the United States for colon cancer screening and prevention. Although the majority of clinically significant cancers may develop in the classic manner, there is evidence that suggests the existence of an alternative, although less common pathway originating from so-called non-polypoid lesions. We have used Surface Enhanced Laser Desorption/Ionization Time of Flight Mass Spectrometry (SELDI-TOF) to preliminarily identify differences in the protein expression between normal polypoid, and cancerous lesions. Successful identification of differences, whether quantitative or qualitative, in the protein patterns from the polypoid and non-polypoid lesions will provide a novel approach to looking at the molecular pathogenesis of colorectal cancer by using proteomics rather than molecular methods and may allow for the development of clinical markers for screening and surveillance of colorectal cancers.

Chronic hepatitis C affects about 3 million adults in the United States. Current treatment is aimed at eliminating the virus to prevent progression and, hopefully, promote regression of hepatic fibrosis. Approximately half of the patients treated for hepatitis C fail to clear the virus. Presently the only proven method of assessing the effect of therapy on hepatic fibrosis is liver biopsy which is both invasive and expensive. In addition, it is also impractical to perform biopsies repeatedly on the same patient and biopsies may not accurately reflect what is occurring in the liver. Thus, most clinicians agree that serum markers would be very helpful in identifying patients at increased risk for fibrosis. As part of the initial investigation to identify potential markers we are using serum from patients with Hepatitis C with various stages of fibrosis and SELDI-TOF to determine if differences in serum protein patterns exist. In conjunction with routine clinical laboratory results, markers identified by SELDI-TOF could offer advantages in the assessment and management of patients with hepatitis C who are undergoing treatment or simply being followed in a clinic.

Selected Publications
  1. Mohammad AA, Elefano EC, Leigh D, Stredler D, Okorodudu AO, Petersen JR. Using computer simulation to study the impact of increasing test volume on turn around times of STAT samples on ci8000intergrated chemistry and immunoassay analyzer. Clin Chem 2004;50:1952-55
  2. Wu J, Petersen JR, Mohammad AA, Okorodudu AO. Point-of-Care hemoglobin measurement by Stat-Site MHgb reflectance meter. Point of Care, J Near-Patient Testing Tech 2:8-11; 2003
  3. Shore J, Petersen JR, VanderJagt DJ, Glew RH. Hypocholesterolemia in African-American Adults with Sickle Cell Disease in the United States. J Natl Med Assoc. 95:813-17; 2003
  4. Chen J, Wang L, Chen JJ-Y, Sahu GK, Tyring S, Ramsey K, Indrikovs AJ, Petersen JR, Paar D, Cloyd MW. Detection of anti-HIV antibodies which recognize conformational epitopes of gp160 allows early diagnosis of HIV infection. J. Infec. Dis. 186:321-31; 2002
  5. DeHoyos DR, Mann P, Okorodudu AO, Mohammad AA, Petersen JR. Development of a website for a decentralized point of care testing program. Point of Care, J Near-Patient Testing Tech 1:63-70; 2002
  6. Hudnall, SD, Alperin, JB, Petersen, JR. Composite Nodular Lymphocyte Predominance Hodgkin’s Disease and Gamma Heavy Chain Disease. Arch. Path. Lab. Med. 125:803-7; 2001
  7. Youh C, Elghetany MT, Petersen JR, Mohammad AA, Okorodudu AO. Accuracy and precision of point-of-care testing for glucose and prothrombin time at the critical care units. Clin. Chim. Acta. 307:119-123; 2001
  8. Chance JJ, Lio DJ, Sokoll LJ, Silberman MA, Engelstad ME, Nichols JH, Liu X, Mohammad AA, Petersen JR, Okorodudu AO. Multiiple site analytical evaluation of a portable blood gas/electrolyte analyzer for point of care testing. Crit. Care Med. 28:2081-5; 2000.
  9. Okorodudu AO, Youh C, Elghetany MT, Petersen JR, Mohammad AA. POCT accuracy and precision. Adv. Admin. Lab. 9:8-9; 2000
  10. Liu X, Turner B, Mohammad AA, Reisner B, Okorodudu AO, Petersen JR. Prospective study IgM to T. Gondii on the Beckman Coulter’s Access immunoassay system and comparison with Zeus ELISA and Gull IFA assays. Diag. Microbiol. Infect. Dis. 36:237-39; 2000
  11. Rao LV, Okorodudu AO, Elghetany MT, Petersen JR. Stability of prothrombin time and activated partial thromboplastin time tests under different storage conditions. Clin. Chim. Acta. 300:13-21; 2000
  12. Petersen JR, Linde MK, Bissell MG. Possible association of decreased total cholesterol and severity of disease in elderly hospitalized patients. Clin. Chem. Acta 290:213-20; 2000.
  13. Mohammad AA, Fujinari E, Okorodudu AO, Petersen JR. Apparatus and Method for Interfacing capillary electrophoresis and chemiluminesence nitrogen detection for analysis of nitrogen-containing compounds. J. Chromatogr. A. 868:121-25; 2000
  14. Rao LV, Petersen JR, Bissell MG, Okorodudu AO, Mohammad AA. Development of a urinary free cortisol using solid-phase extraction capillary electrophoresis (SPE-CE). J. Chrom. B 730:123-28; 1999
  15. Rao LV, Petersen JR, Mohammad AA, Bissell MG, Okorodudu AO. Cost-effective utilization of CKMB mass and activity assays. Lab. Med. 30:271-75; 1999.
  16. Nix RJ, Mohammad AA, Petersen JR, Okorodudu AO. Interference with Glucose and Lactate Measurements in Blood gas/Electrolyte/Metabolite and Routine Clinical Chemistry Analyzers. In: Proceedings of the 17th International Symposium on the Confluence of Critical Care Analysis and Near Patient Testing Pages 220-31; 1998
  17. Nix RJ, Elghetany, MT, Petersen JR, Mohammad AA, Okorodudu AO. Dehydration: Its manifestation, complications, laboratory findings, and treatment. Adv. Med. Lab. Prof. July:7-10; 1998
  18. Petersen JR, Bissell MG. Leveling the playing field: The economics of robotics in the clinical laboratory. MLO 30:42-45; 1998.
  19. Rao LV, James OA, Mann L, Mohammad AA, Okorodudu AO, Bissell MG, Petersen JR. Evaluation of Technicon Immuno 1 toxoplasma IgG assay in the prenatal diagnosis of toxoplasmosis. Diag. Microbiol. Infect. Dis. 27:13-15; 1997
  20. Bissell MG, Okorodudu AO, Petersen JR, Mohammad AA. Laser induced resonance energy transfer - A novel approach for avoiding derivatization in LIF detection in Capillary Electrophoresis. Part B Environmental Applications. J. Chrom. A 767:217-21; 1997
  21. Rao, LV, Petersen JR, Bissell MG, Okorodudu AO, Mohammad AA. Specific Determination of Urinary Free Cortisol by Solid-Phase microparticle extraction capillary electrophoresis using fused silica capillaries. Clin. Chem. 43:1801-03; 1997
  22. Mohammad AA, Petersen JR, Dow P, Bissell MG, Regner G, Meier AP, Guadagno PA. Clinical application of Capillary Isoelectric Focusing on Fused Silica Capillaries for Determination of Hemoglobin Variants. Clin. Chem. 43:1798-99; 1997
  23. Valbuena GA, Petersen JR, Bissell MG, Mohammad AA. Anionic-zwitterionic mixed micelles in micellar electrokinetic separation of Clinically Relevant Steroids. J. Chrom. A 781:467-74; 1997
  24. Petersen JR, Smith ER, Okorodudu AO, Bissell MG. Utilization of LDH isoenzymes in the routine diagnosis of myocardial infarction. CLMR 11:103-7; 1997
  25. Smith E, Petersen JR, Okorodudu AO, Bissell MG. Does the addition of unconjugated esteriol in maternal serum screening improve the detection of trisomy 21 and 18: a meta-analysis. CLMR 10:176-181; 1996
  26. Petersen JR, Smith E, Okorodudu AO, Bissell MG. Comparsion of four methods (L/S ratio, TDx FLM, Lamellar bodies) for fetal lung maturity using meta-analysis. CLMR 10:169-175; 1996
  27. Mohammad AA, Summers H, Burchfield JE, Petersen JR, Bissell MG, Okorodudu AO. STAT turnaround time: Point-to-Point testing and satellite laboratories. Lab. Med. 27:684-88; 1996.
  28. Petersen JR, Mohammad AA, Okorodudu AO, Bissell MG. Laser induced resonance energy transfer - A novel approach for avoiding derivatization in LIF detection in Capillary Electrophoresis. Part A Clinical Applications. J. Chrom. A 744:37-44; 1996
  29. James OA, Petersen JR, Bissell MG, Okorodudu AO, Harris PL, Clayton SS, Mohammad AA. Improved sample retrieval and turn around time (TAT) in the clinical lab using a spreadsheet template for sample storage. Clin. Chem. 9:1571-73; 1996
  30. Abubaker MA, Bissell MG, Petersen JR. Rapid profiling of clinically relevant steroids by micellar electrokinetic capillary chromatography. J. Cap. Electro. 2:105-10; 1995
  31. Mohammad AA, Bissell MG, Petersen JR. Micellar electrokinetic capillary chromatography to separate steroids that are elevated in congenital adrenal hyperplasia. Clin. Chem. 41:1369-70; 1995
  32. Abubaker MA, Petersen JR, Bissell MG. Micellar electrokinetic capillary chromatography separation of steroids in urine by trioctylphosphine oxide and cationic surfactant. J. Chrom. B 674:31-38; 1995
  33. Abubaker MA, Filos D, Petersen JR. Comparison of four competitive immunoassay systems used for thyroid function testing. Clin. Chem. 41:1538-1540; 1995
  34. Greenwell D, Petersen J, Kulvicki A, Harder J, Goldblum R, Neal D, Jr. Urinary secretory IgA and free secretory component in pyelonephritis. Am. J. Kid. Dis. 26:590-594; 1995
  35. Goldberg MA, Schneider TJ, Khan S, Petersen JR. Clinical validation of a RIA for natural and recombinant erythropoietin in serum and plasma. Clin. Biochem. 26:183-89; 1993
  36. Petersen JR, Morgan B, Roden K, Imbing Jr., F. Plasma hemoglobin determination using the Cobas Fara. Clin. Chem. News 19:26; 1993
  37. Scott MG, Cuca GC, Petersen JR, Lyle LR, Burleigh BD, Daughaday WH. Specific immunoradiometric assay of insulin-like growth factor with use of monoclonal antibodies. Clin. Chem. 33:2019-23; 1987
  38. Mariano PS, Glover GI, Petersen JR. Evidence for pH-dependent irreversible formation of a stable conformation of phenacyl--chymotrypsin. Biochem. J. 171:115; 1978
  39. Sankaran L, Proffitt RT, Petersen JR, Pogell BM. Specific factors influencing histotypic aggregation of chick embryo hepatocytes. Proc. Nat'l. Acad. Sci. 74:4486; 1977
  40. Glover GI, Mariano PS, Petersen JR. A reinvestigation of the phenacyl bromide modification of -chymotrypsin. Biochem. 15:3754; 1976
  41. DeBruin KE, Petersen JR. Steric and electronic effects on the stereochemistry of the alkaline hydrolysis of acyclic dialkyoxyphosphonium salts. J. Org. Chem. 37:2272; 1972
  42. Wiegand BH, Petersen JR, Yu SL. A convenient synthesis of aryl phenyl and alkyl phenyl sulfides. Int. J. Sulfur Chem 2(4):295; 1972

Search PubMed database for John Petersen